The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
 
A. Oliver Sartor
Stock and Other Ownership Interests - GlaxoSmithKline; Lilly; Noria Pharma Solutions
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; Bristol-Myers Squibb; Celgene; Constellation Pharmaceuticals; Dendreon; EMD Serono; Endocyte; Johnson & Johnson; Oncogenex; Pfizer; Progenics; Sanofi
Research Funding - Bayer (Inst); Endocyte (Inst); Innocrin Pharma (Inst); InVitae (Inst); Johnson & Johnson (Inst); Merck; Sanofi (Inst)
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Progenics; Sanofi
 
Michael J. Morris
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; Bayer; Blue Earth Diagnostics; Endocyte; Tokai Pharmaceuticals; Tolmar
Speakers' Bureau - ORIC Pharmaceuticals
Research Funding - Bayer (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Progenics (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bayer; Endocyte
 
Bernd J Krause
No Relationships to Disclose